{"symbol":"BMY","provider":"yahoo-finance","fetchedAt":"2025-12-24T01:49:27.927Z","asOfDate":"2025-12-23","articles":[{"id":"c969e3ec-7e0c-3c35-9edd-c270b87ff7e9","title":"Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact","url":"https://finance.yahoo.com/news/bristol-myers-bmy-offers-eliquis-222335062.html","publisher":"Insider Monkey","publishedAt":"2025-12-23T22:23:35.000Z","relatedTickers":[],"mainIdea":"Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact","summary":"Insider Monkey: Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact. Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to […]"},{"id":"c3618b22-c259-3b5d-8c97-07b84b79431b","title":"Will the Recent Pricing Deal With the Government Impact BMY's Sales?","url":"https://finance.yahoo.com/news/recent-pricing-deal-government-impact-190900119.html","publisher":"Zacks","publishedAt":"2025-12-23T19:09:00.000Z","relatedTickers":["JNJ","MRK","PFE"],"mainIdea":"Will the Recent Pricing Deal With the Government Impact BMY's Sales?","summary":"Zacks: Will the Recent Pricing Deal With the Government Impact BMY's Sales?. BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis. Related tickers mentioned: JNJ, MRK, PFE."},{"id":"fe7d0059-6e4d-3def-b51c-bbe5a11f10dc","title":"Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick","url":"https://finance.yahoo.com/news/momentum-investor-1-stock-could-145003209.html","publisher":"Zacks","publishedAt":"2025-12-23T14:50:03.000Z","relatedTickers":[],"mainIdea":"Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick","summary":"Zacks: Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick. Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores."},{"id":"62a09c64-5a85-3fea-b48b-6b60f004c5cf","title":"Office Introverts Want the Boss to Understand Their Plight","url":"https://finance.yahoo.com/m/62a09c64-5a85-3fea-b48b-6b60f004c5cf/office-introverts-want-the.html","publisher":"The Wall Street Journal","publishedAt":"2025-12-23T10:30:00.000Z","relatedTickers":[],"mainIdea":"Office Introverts Want the Boss to Understand Their Plight","summary":"The Wall Street Journal: Office Introverts Want the Boss to Understand Their Plight. The quietest employees have begun speaking up about the ways the office doesn’t work for them. Time for recharge lounges."},{"id":"2dc54035-691e-35fa-af3d-c59a4fb8694a","title":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","url":"https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html","publisher":"Zacks","publishedAt":"2025-12-22T18:43:00.000Z","relatedTickers":["ABBV","IHE","JNJ","LLY","PFE","VHCIX","VHT","XLV","^GSPC"],"mainIdea":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","summary":"Zacks: Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends. XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership. Related tickers mentioned: ABBV, IHE, JNJ, LLY, PFE, VHCIX, VHT, XLV, ^GSPC."},{"id":"61011386-a8c8-3e29-86b1-2eda14114540","title":"Analyst Report: Bristol-Myers Squibb Company","url":"https://finance.yahoo.com/m/61011386-a8c8-3e29-86b1-2eda14114540/analyst-report%3A-bristol-myers.html","publisher":"Morningstar Research","publishedAt":"2025-12-22T16:35:00.000Z","relatedTickers":[],"mainIdea":"Analyst Report: Bristol-Myers Squibb Company","summary":"Morningstar Research: Analyst Report: Bristol-Myers Squibb Company. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group."},{"id":"6a874f74-6733-32d9-a28a-ca2b7e5c1e9d","title":"Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up","url":"https://finance.yahoo.com/news/cytokinetics-wins-fda-approval-cardiovascular-142900683.html","publisher":"Zacks","publishedAt":"2025-12-22T14:29:00.000Z","relatedTickers":["CYTK"],"mainIdea":"Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up","summary":"Zacks: Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up. CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology. Related tickers mentioned: CYTK."}]}
